The Medicines Co. (MDCO)

36.04
0.39 1.10
NASDAQ : Health Technology
Prev Close 36.43
Open 36.80
Day Low/High 36.28 / 36.81
52 Wk Low/High 16.69 / 41.33
Volume 37.34K
Avg Volume 1.46M
Exchange NASDAQ
Shares Outstanding 79.28M
Market Cap 2.86B
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Medicines (MDCO) Moving On Heavy Pre-Market Trading

Medicines (MDCO) Moving On Heavy Pre-Market Trading

Trade-Ideas LLC identified Medicines (MDCO) as a pre-market mover with heavy volume candidate

The Medicines Company Prices $350 Million Of Convertible Notes

The Medicines Company Prices $350 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it has priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023.

Barbarian At The Gate: Medicines (MDCO)

Barbarian At The Gate: Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

The Medicines Company Announces Intention To Offer $350 Million Of Convertible Notes

The Medicines Company Announces Intention To Offer $350 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it proposes to offer $350 million aggregate principal amount of convertible senior notes due 2023, subject to market conditions and other factors.

The Medicines Company Completes Patient Enrollment For ORION-1 Study Of PCSK9si

The Medicines Company Completes Patient Enrollment For ORION-1 Study Of PCSK9si

The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the ORION-1 study of PCSK9si, its investigational first-in-class RNA interference (RNAi) proprotein convertase subtilisin/kexin type...

The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)

The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)

The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the Phase 3 TANGO 1 study of CARBAVANCE® (meropenem-vaborbactam), an investigational agent being developed for the treatment of...

The Medicines Company To Present At Two Upcoming Investor Conferences

The Medicines Company To Present At Two Upcoming Investor Conferences

The Medicines Company (NASDAQ:MDCO) today announced that the company is scheduled to make presentations at the following June investor conferences: Jefferies 2016 Healthcare Conference - New York City, Tuesday,...

5 Stocks Insiders Are Scooping Up Right Now

5 Stocks Insiders Are Scooping Up Right Now

Insiders at these five companies have been buying shares of their own stock recently. Should you?

The Medicines Company Appoints Tony Kingsley As President And Chief Operating Officer

The Medicines Company Appoints Tony Kingsley As President And Chief Operating Officer

The Medicines Company (NASDAQ:MDCO) has announced the appointment of Tony Kingsley as President and Chief Operating Officer.

The Medicines Company Reports First-Quarter 2016 Business And Financial Results

The Medicines Company Reports First-Quarter 2016 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the first quarter ended March 31, 2016.

The Medicines Company Agrees To Divest Non-Core Cardiovascular Assets To Chiesi Farmaceutici S.p.A.

The Medicines Company Agrees To Divest Non-Core Cardiovascular Assets To Chiesi Farmaceutici S.p.A.

The Medicines Company (NASDAQ:MDCO) today announced that it has entered into a definitive agreement to sell Cleviprex® (clevidipine), Kengreal® (cangrelor) and the Company's rights to Argatroban for Injection to...

The Medicines Company To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

The Medicines Company To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Tuesday, May 10, 2016, at 8:00 AM PT (11:00 AM ET).

The Medicines Company To Announce First Quarter Financial Results On May 9, 2016

The Medicines Company To Announce First Quarter Financial Results On May 9, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for May 9 th at 8:30 a.

FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)

FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)

The Medicines Company (NASDAQ:MDCO) today announced that the U.S.

The Medicines Company Announces Participation At 2016 European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) To Be Held April 9-12 In Amsterdam

The Medicines Company Announces Participation At 2016 European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) To Be Held April 9-12 In Amsterdam

The Medicines Company (NASDAQ:MDCO) today announced that investigators will present data for the Phase 3 investigational agent CARBAVANCE® (meropenem-vaborbactam) on activity against newly discovered BKC-1...

The Medicines Company Announces Participation At 2016 American College Of Cardiology (ACC) Scientific Sessions In Chicago

The Medicines Company Announces Participation At 2016 American College Of Cardiology (ACC) Scientific Sessions In Chicago

The Medicines Company (NASDAQ:MDCO) today announced that investigators will present new analyses from high-risk percutaneous coronary intervention (PCI) patient subgroups from the CHAMPION PHOENIX study with its...

Insider Trading Alert - MDCO, DXCM And WMGI Traded By Insiders

Insider Trading Alert - MDCO, DXCM And WMGI Traded By Insiders

Stocks with insider trader activity include MDCO, DXCM and WMGI

The Medicines Company To Present At Cowen And Company 36th Annual Health Care Conference

The Medicines Company To Present At Cowen And Company 36th Annual Health Care Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston, MA on Wednesday, March 9, 2016, at 8:40 AM EST.

The Medicines Company To Participate In 2016 RBC Capital Markets Global Healthcare Conference

The Medicines Company To Participate In 2016 RBC Capital Markets Global Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to participate at the 2016 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, February 23 rd at 8:00am EST.

Medicines (MDCO) Stock Price Target Lowered at Jefferies

Medicines (MDCO) Stock Price Target Lowered at Jefferies

Jefferies decreased its price target on Medicines (MDCO) stock and maintained its ‘buy’ rating.

Medicines Co. (MDCO) Stock Jumping on Q4 Results

Medicines Co. (MDCO) Stock Jumping on Q4 Results

Medicines Co. (MDCO) stock is climbing on Wednesday afternoon following the release of its 2015 fourth quarter results before today’s market open.

The Medicines Company Reports Fourth-Quarter And Full-Year 2015 Business And Financial Results

The Medicines Company Reports Fourth-Quarter And Full-Year 2015 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the fourth quarter and full year ended December 31, 2015.

Clive Meanwell, MD, PhD Receives Dr. Sol J. Barer Award At BioNJ Gala Event

Clive Meanwell, MD, PhD Receives Dr. Sol J. Barer Award At BioNJ Gala Event

The Medicines Company (NASDAQ:MDCO) today announced that its founder and Chief Executive Officer, Clive Meanwell, MD, PhD, has been awarded the 2016 Dr.

The Medicines Company To Announce Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 17, 2016

The Medicines Company To Announce Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 17, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Wednesday, February 17 th at 8:30 a.

The Medicines Company Appoints Alexander J. Denner, Ph.D. To Its Board Of Directors

The Medicines Company Appoints Alexander J. Denner, Ph.D. To Its Board Of Directors

The Medicines Company (NASDAQ:MDCO) today announced that it has appointed Alexander J.

The Medicines Company To Participate In Leerink Partners 5th Annual Global Healthcare Conference

The Medicines Company To Participate In Leerink Partners 5th Annual Global Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to participate at the Leerink Partners 5 th Annual Global Healthcare Conference in New York, NY on Wednesday, February 10 th at 10:40am EST.

The Medicines Company Completes Divestiture Of Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company Completes Divestiture Of Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company (NASDAQ:MDCO) today announced that it has completed the divestiture of its hemostasis portfolio to Mallinckrodt plc.

Medicines (MDCO) Highlighted As Today's Perilous Reversal Stock

Medicines (MDCO) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Medicines (MDCO) as a "perilous reversal" (up big yesterday but down big today) candidate

Why Medicines (MDCO) Stock is Advancing Today

Why Medicines (MDCO) Stock is Advancing Today

Medicines (MDCO) stock is climbing on Wednesday afternoon as the company explores a sale of itself.

Strong On High Volume: Medicines (MDCO)

Strong On High Volume: Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a strong on high relative volume candidate